Prokaryote-expressed M2e protein improves H9N2 influenza vaccine efficacy and protection against lethal influenza a virus in mice

Virology Journal

Volumn 10, Issue , 2013, Pages

  Kim, Eun Ha ^a   Lee, Jun Han ^a   Pascua, Philippe Noriel Q ^a   Song, Min Suk ^a   Baek, Yun Hee ^a   Kwon, Hyeok Il ^a   Park, Su Jin ^a   Lim, Gyo Jin ^a   Decano, Arun ^a   Chowdhury, Mohammed Ye ^b   Seo, Su Kyung ^b   Song, Man Ki ^c   Kim, Chul Joong ^b   Choi, Young Ki ^a  

^a Chungbuk National University College of Medicine   (South Korea)

^b Chungnam National University   (South Korea)

^c International Vaccine Institute   (South Korea)

Author keywords

Escherichia coli; Inactivated vaccine; Influenza A virus; M2e protein

Indexed keywords

INFLUENZA VACCINE; PROTEIN M2;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CONTROL GROUP; CROSS PROTECTION; DEATH; DRUG EFFICACY; FEMALE; IMMUNIZATION; INFLUENZA; INFLUENZA VIRUS A; INFLUENZA VIRUS A H9N2; LETHALITY; MOUSE; NONHUMAN; PROKARYOTE; PROTEIN EXPRESSION; SURVIVAL;

AVIAN INFLUENZA VIRUS; ESCHERICHIA COLI; INFLUENZA A VIRUS; MUS; ORTHOMYXOVIRIDAE; PROKARYOTA;

EID: 84875668090     PISSN: None     EISSN: 1743422X     Source Type: Journal    
DOI: 10.1186/1743-422X-10-104     Document Type: Article

References (47)

1. Antiviral activity of Anaferon (pediatric formulation) in mice infected with pandemic influenza virus A(H1N1/09). Shishkina LN, Skarnovich MO, Kabanov AS, Sergeev AA, Olkin SE, Tarasov SA, Belopolskaya MV, Sergeeva SA, Epstein OI, Malkova EM, Bull Exp Biol Med 2010 149 612 614 10.1007/s10517-010-1006-0 21165400
2. Highly pathogenic H5N1 avian influenza virus: cause of the next pandemic? Pappaioanou M, Comp Immunol Microbiol Infect Dis 2009 32 287 300 10.1016/j.cimid.2008.01.003 19318178
3. Pediatric influenza. Bramley AM, Bresee J, Finelli L, Centers for Disease Control and Prevention (CDC), Pediatr Nurs 2009 35 335 345 20166462
4. Clinical effectiveness of oseltamivir and zanamivir for treatment of influenza A virus subtype H1N1 with the H274Y mutation: a Japanese, multicenter study of the 2007-2008 and 2008-2009 influenza seasons. Kawai N, Ikematsu H, Hirotsu N, Maeda T, Kawashima T, Tanaka O, Yamauchi S, Kawamura K, Matsuura S, Nishimura M, Clin Infect Dis 2009 49 1828 1835 10.1086/648424 19911968
5. Vaccines for seasonal and pandemic influenza. Nichol KL, Treanor JJ, J Infect Dis 2006 194 Suppl 2 111 S118 17163383
6. Oseltamivir-resistant pandemic H1N1/2009 influenza virus possesses lower transmissibility and fitness in ferrets. Duan S, Boltz DA, Seiler P, Li J, Bragstad K, Nielsen LP, Webby RJ, Webster RG, Govorkova EA, PLoS Pathog 2010 6 1001022 10.1371/journal.ppat.1001022 20686654
7. Influenza A viruses: why focusing on M2e-based universal vaccines. Ebrahimi SM, Tebianian M, Virus Genes 2011 42 1 8 10.1007/s11262-010-0547-7 21082230
8. Characterization of immunity induced by M2e of influenza virus. Wu F, Huang JH, Yuan XY, Huang WS, Chen YH, Vaccine 2007 25 8868 8873 10.1016/j.vaccine.2007.09.056 18061317 (Pubitemid 350199590)
9. Genetic control of immune responses to influenza A matrix 2 protein (M2). Misplon JA, Lo CY, Gabbard JD, Tompkins SM, Epstein SL, Vaccine 2010 28 5817 5827 10.1016/j.vaccine.2010.06.069 20600476
10. Influenza A virus M2 protein: monoclonal antibody restriction of virus growth and detection of M2 in virions. Zebedee SL, Lamb RA, J Virol 1988 62 2762 2772 2455818
11. Preclinical study of influenza virus A M2 peptide conjugate vaccines in mice, ferrets, and rhesus monkeys. Fan J, Liang X, Horton MS, Perry HC, Citron MP, Heidecker GJ, Fu TM, Joyce J, Przysiecki CT, Keller PM, Vaccine 2004 22 2993 3003 10.1016/j.vaccine.2004.02.021 15297047 (Pubitemid 39037199)
12. Protection of mice against influenza A virus challenge by vaccination with baculovirus-expressed M2 protein. Slepushkin VA, Katz JM, Black RA, Gamble WC, Rota PA, Cox NJ, Vaccine 1995 13 1399 1402 10.1016/0264-410X(95)92777-Y 8578816
13. Modified M2 proteins produce heterotypic immunity against influenza A virus. Frace AM, Klimov AI, Rowe T, Black RA, Katz JM, Vaccine 1999 17 2237 2244 10.1016/S0264-410X(99)00005-5 10403591 (Pubitemid 29225675)
14. Evolving strategies for the prevention of influenza infection: potential for multistrain targeting. Livingston BD, Higgins D, Van NG, BioDrugs 2006 20 335 340 10.2165/00063030-200620060-00003 17176120 (Pubitemid 46089659)
15. A universal influenza A vaccine based on the extracellular domain of the M2 protein. Neirynck S, Deroo T, Saelens X, Vanlandschoot P, Jou WM, Fiers W, Nat Med 1999 5 1157 1163 10.1038/13484 10502819 (Pubitemid 29474420)
16. Induction of influenza type A virus-specific resistance by immunization of mice with a synthetic multiple antigenic peptide vaccine that contains ectodomains of matrix protein 2. Mozdzanowska K, Feng J, Eid M, Kragol G, Cudic M, Otvos L Jr, Gerhard W, Vaccine 2003 21 2616 2626 10.1016/S0264-410X(03)00040- 9 12744898 (Pubitemid 36561354)
17. An H5N1 M2e-based multiple antigenic peptide vaccine confers heterosubtypic protection from lethal infection with pandemic 2009 H1N1 virus. Zhao G, Sun S, Du L, Xiao W, Ru Z, Kou Z, Guo Y, Yu H, Jiang S, Lone Y, Virol J 2010 7 151 10.1186/1743-422X-7-151 20624292
18. Expression and immunity of fused protein H1N1 M2e and cholera toxin B. Yang XF, Jiang Y, Li WY, Kuang Y, Jiang ZH, Wang FP, Li MY, Xi Bao Yu Fen Zi Mian Yi Xue Za Zhi 2008 24 263 266 18328189
19. Potent immunogenicity and efficacy of a universal influenza vaccine candidate comprising a recombinant fusion protein linking influenza M2e to the TLR5 ligand flagellin. Huleatt JW, Nakaar V, Desai P, Huang Y, Hewitt D, Jacobs A, Tang J, McDonald W, Song L, Evans RK, Vaccine 2008 26 201 214 10.1016/j.vaccine.2007.10.062 18063235 (Pubitemid 50008089)
20. Influenza virus-like particles containing M2 induce broadly cross protective immunity. Song JM, Wang BZ, Park KM, Van RN, Quan FS, Kim MC, Jin HT, Pekosz A, Compans RW, Kang SM, PLoS One 2011 6 14538 10.1371/journal.pone. 0014538 21267073
21. Viruslike particle vaccine induces protection against respiratory syncytial virus infection in mice. Quan FS, Kim Y, Lee S, Yi H, Kang SM, Bozja J, Moore ML, Compans RW, J Infect Dis 2011 204 987 995 10.1093/infdis/jir474 21881112
22. The polymerase acidic protein gene of influenza a virus contributes to pathogenicity in a mouse model. Song MS, Pascua PN, Lee JH, Baek YH, Lee OJ, Kim CJ, Kim H, Webby RJ, Webster RG, Choi YK, J Virol 2009 83 12325 12335 10.1128/JVI.01373-09 19793828
23. Heat inactivation of avian influenza and Newcastle disease viruses in egg products. Swayne DE, Beck JR, Avian Pathol 2004 33 512 518 10.1080/ 03079450400003692 15545031 (Pubitemid 39501094)
24. Evaluation of different methods of inactivation of Newcastle disease virus and avian influenza virus in egg fluids and serum. King DJ, Avian Dis 1991 35 505 514 10.2307/1591214 1835374
25. Thermal inactivation of H5N1 high pathogenicity avian influenza virus in naturally infected chicken meat. Thomas C, Swayne DE, J Food Prot 2007 70 674 680 17388058 (Pubitemid 46446991)
26. Thermal inactivation of avian influenza and Newcastle disease viruses in chicken meat. Thomas C, King DJ, Swayne DE, J Food Prot 2008 71 1214 1222 18592748 (Pubitemid 351829817)
27. Human infection with influenza H9N2. Peiris M, Yuen KY, Leung CW, Chan KH, Ip PL, Lai RW, Orr WK, Shortridge KF, Lancet 1999 354 916 917 10.1016/S0140-6736(99)03311-5 10489954 (Pubitemid 29424025)
28. Characterization of the pathogenicity of members of the newly established H9N2 influenza virus lineages in Asia. Guo YJ, Krauss S, Senne DA, Mo IP, Lo KS, Xiong XP, Norwood M, Shortridge KF, Webster RG, Guan Y, Virology 2000 267 279 288 10.1006/viro.1999.0115 10662623 (Pubitemid 30123610)
29. Pathogenesis of emerging avian influenza viruses in mammals and the host innate immune response. Maines TR, Szretter KJ, Perrone L, Belser JA, Bright RA, Zeng H, Tumpey TM, Katz JM, Immunol Rev 2008 225 68 84 10.1111/j.1600-065X. 2008.00690.x 18837776
30. Continuing evolution of H9N2 influenza viruses in Southeastern China. Choi YK, Ozaki H, Webby RJ, Webster RG, Peiris JS, Poon L, Butt C, Leung YH, Guan Y, J Virol 2004 78 8609 8614 10.1128/JVI.78.16.8609-8614.2004 15280470 (Pubitemid 39025127)
31. Neuraminidase inhibitors for influenza. Moscona A, N Engl J Med 2005 353 1363 1373 10.1056/NEJMra050740 16192481 (Pubitemid 41362704)
32. Research and development of universal influenza vaccines. Du L, Zhou Y, Jiang S, Microbes Infect 2010 12 280 286 10.1016/j.micinf.2010.01.001 20079871
33. Neuraminidase inhibitors for influenza. Moscona A, N Engl J Med 2005 353 1363 1373 10.1056/NEJMra050740 16192481 (Pubitemid 41362704)
34. Sublingual immunization with M2-based vaccine induces broad protective immunity against influenza. Shim BS, Choi YK, Yun CH, Lee EG, Jeon YS, Park SM, Cheon IS, Joo DH, Cho CH, Song MS, PLoS One 2011 6 27953 10.1371/journal.pone. 0027953 22140491
35. Universal M2 ectodomain-based influenza A vaccines: preclinical and clinical developments. Schotsaert M, De FM, Fiers W, Saelens X, Expert Rev Vaccines 2009 8 499 508 10.1586/erv.09.6 19348565
36. Matrix protein 2 vaccination and protection against influenza viruses, including subtype H5N1. Tompkins SM, Zhao ZS, Lo CY, Misplon JA, Liu T, Ye Z, Hogan RJ, Wu Z, Benton KA, Tumpey TM, Emerg Infect Dis 2007 13 426 435 10.3201/eid1303.061125 17552096 (Pubitemid 46348126)
37. Reactions of antibodies with surface antigens of influenza virus. Webster RG, Laver WG, Kilbourne ED, J Gen Virol 1968 3 315 326 10.1099/0022-1317-3-3- 315 5711432
38. Preparation and properties of antibody directed specifically against the neuraminidase of influenza virus. Webster RG, Laver WG, J Immunol 1967 99 49 55 6029282
39. Improved design and intranasal delivery of an M2e-based human influenza A vaccine. De FM, Fiers W, Martens W, Birkett A, Ramne A, Lowenadler B, Lycke N, Jou WM, Saelens X, Centers for Disease Control and Prevention (CDC), Vaccine 2006 24 6597 6601 10.1016/j.vaccine.2006.05.082 16814430 (Pubitemid 46127431)
40. Roles of adjuvant and route of vaccination in antibody response and protection engendered by a synthetic matrix protein 2-based influenza A virus vaccine in the mouse. Mozdzanowska K, Zharikova D, Cudic M, Otvos L, Gerhard W, Virol J 2007 4 118 10.1186/1743-422X-4-118 17974006
41. Influenza A vaccine based on the extracellular domain of M2: weak protection mediated via antibody-dependent NK cell activity. Jegerlehner A, Schmitz N, Storni T, Bachmann MF, J Immunol 2004 172 5598 5605 15100303 (Pubitemid 38542062)
42. Scientific barriers to developing vaccines against avian influenza viruses. Subbarao K, Joseph T, Nat Rev Immunol 2007 7 267 278 10.1038/nri2054 17363960 (Pubitemid 46480953)
43. Influenza type A virus escape mutants emerge in vivo in the presence of antibodies to the ectodomain of matrix protein 2. Zharikova D, Mozdzanowska K, Feng J, Zhang M, Gerhard W, J Virol 2005 79 6644 6654 10.1128/JVI.79.11.6644- 6654.2005 15890902 (Pubitemid 40677295)
44. Evolution of Novel Reassortant A/H3N2 Influenza Viruses in North American Swine and Humans, 2009-2011. Nelson MI, Vincent AL, Kitikoon P, Holmes EC, Gramer MR, J Virol 2012 86 8872 8878 10.1128/JVI.00259-12 22696653
45. Human infections with novel reassortant influenza A(H3N2)v viruses, United States, 2011. Lindstrom S, Garten R, Balish A, Shu B, Emery S, Berman L, Barnes N, Sleeman K, Gubareva L, Villanueva J, Emerg Infect Dis 2012 18 834 837 10.3201/eid1805.111922 22516540
46. Outbreak of Influenza A (H3N2) Virus Among Persons and Swine at a County Fair-Indiana, July 2012. Richards S, House M, Pontones P, Metcalf D, Marsh B, Swenson S, Korslund J, Blanton L, Epperson S, Bigger M, MMWR Morb Mortal Wkly Rep 2012 61 561 22832938
47. A simple method of estimating fifty per cent endpoints. Reed LJ, Muench H, Am J Epidemiol 1938 27 493 497